Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Rheumatology and Therapy|November 11, 2018
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 StudiesPeter Nash, Laura C Coates, Roy Fleischmann, et al.
RMD Open|February 5, 2019
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL BeyondVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 24, 2006
Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mousePatrick Yue, Takayasu Arai, Masahiro Terashima, et al.
NPJ Regenerative Medicine|February 10, 2026
Telomere shortening in laminopathic dilated cardiomyopathyAlex C Y Chang, Gaspard Pardon, Andrew C H Chang, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor designGui-Bai Liang, Xiaoxia Qian, Tesfaye Biftu, et al.
The American Journal of Gastroenterology|January 29, 2025
Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical ProgramAndres J Yarur, Millie D Long, Joana Torres, et al.
BMJ Open Gastroenterology|September 1, 2025
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programmeMaría Chaparro, Remo Panaccione, Bruce E Sands, et al.
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
RMD Open|June 2, 2022
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trialVictoria Navarro-Compán, James Cheng-Chung Wei, Filip Van den Bosch, et al.
Inflammatory Bowel Diseases|December 13, 2024
Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical ProgramAndres J Yarur, Michael V Chiorean, Jessica R Allegretti, et al.
Pageof 13